Machiels, Jean-PascalSalazar, RamónRottey, SylvieDuran, IgnacioDirix, LucGeboes, KarenWilkinson-Blanc, ChristinePover, GillianAlvis, SimonChampion, BrianFisher, KerryMcElwaine-John, HilaryBeadle, JohnCalvo, Emiiano2020-08-242020-08-242019-01-28Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019 Jan 28;7(1):20.http://hdl.handle.net/10668/3170Artículo editado por BMC en 2019. La revista "Journal for ImmunoTherapy of Cancer" pasa a ser propiedad de BMJ en 2020, quien actualmente la edita y distribuye.Background: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV) dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a suitable schedule for repeated cycles. Methods: Sixty-one patients with advanced epithelial tumors unresponsive to conventional therapy were enrolled and received enadenotucirev monotherapy as part of this study. During the phase 1a dose escalation (n = 22) and expansion (n = 9), delivery of enadenotucirev between 1 × 1010 and 1 × 1013 viral particles (vp) on days 1, 3, and 5 (single cycle) was used to determine an appropriate MTD. Subsequent treatment cohorts (phase 1a, n = 6 and phase 1b, n = 24) examined the feasibility of repeated dosing cycles in either 3-weekly or weekly dosing regimens. Results: Enadenotucirev displayed a predictable and manageable safety profile at doses up to the MTD of 3 × 1012 vp, irrespective of infusion time or dosing schedule. The most commonly reported treatment-emergent adverse events (TEAEs) of grade 3 or higher were hypoxia, lymphopenia, and neutropenia. The frequency of all TEAEs (notably pyrexia and chills) was highest within 24 h of the first enadenotucirev infusion and decreased upon subsequent dosing. Additionally, delivery of three doses of enadenotucirev over 5 days optimized pharmacokinetic and chemokine profiles in the circulation over time. Conclusions: This study provides key clinical data in patients with solid epithelial tumors following treatment with IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other therapeutic agents at doses up to the MTD of 3 × 1012 vp.enClinical TrialsPharmacokinetics and pharmacodynamicsEnadenotucirevOncolytic adenovirusEpithelial solid tumorIntravenousFarmacocinéticaFarmacologíaEnsayos clínicos como asuntoAdenoviridaeCarcinomaInyecciones intravenosasMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, IntravenousMedical Subject Headings::Organisms::Viruses::DNA Viruses::AdenoviridaeMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::CytokinesMedical Subject Headings::Persons::Persons::Age Groups::AdultMedical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::PharmacologyMedical Subject Headings::Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Kinetics::PharmacokineticsMedical Subject Headings::Persons::Persons::Age Groups::Adult::AgedMedical Subject Headings::Organisms::Viruses::Oncolytic VirusesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Oncolytic VirotherapyA phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)research article30691536open access10.1186/s40425-019-0510-72051-1426PMC6348630